Drug Metabolism and Disposition · 2002 · 324 citations · 81 references
MedicinePharmacokineticsPharmacologyBiochemical PharmacologyClinical PharmacologyDrug DiscoveryCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesPreclinical Drug EvaluationCyp450-mediated InteractionsCytochrome P450 1A2Cytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 Reaction MechanismsCytochrome P450 Substrate SpecificityEnzyme ActivityProbe Substrates
Industry routinely uses in‑vitro probe reactions to evaluate a drug’s effect on CYP enzymes, extrapolating results from a single probe to all substrates of that enzyme, with common probes such as phenacetin for CYP1A2 and testosterone for CYP3A4, but the activity of a probe depends on specific experimental conditions. The study aims to emphasize that selecting appropriate probe substrates and experimental conditions is essential for accurate in‑vitro CYP interaction studies and for reliable extrapolation to in‑vivo outcomes. The authors reviewed validation data for common probe reactions—including phenacetin, coumarin, 7‑ethoxy‑4‑trifluoromethyl coumarin, tolbutamide, S‑mephenytoin, bufuralol, chlorzoxazone, testosterone, caffeine, S‑warfarin, dextromethorphan, and midazolam—to assess their suitability. The available information indicates that better probe substrates are still needed for some enzymes.
Pharmaceutical industry investigators routinely evaluate the potential for a new drug to modify cytochrome P450 (P450) activities by determining the effect of the drug on in vitro probe reactions that represent activity of specific P450 enzymes. The in vitro findings obtained with one probe substrate are usually extrapolated to the compound9s potential to affect all substrates of the same enzyme. Due to this practice, it is important to use the right probe substrate and to conduct the experiment under optimal conditions. Surveys conducted by reviewers in CDER indicated that the most common in vitro probe reactions used by industry investigators include the following: phenacetin <i>O</i>-deethylation for CYP1A2, coumarin 7-hydroxylation for CYP2A6, 7-ethoxy-4-trifluoromethyl coumarin <i>O</i>-dealkylation for CYP2B6, tolbutamide 4′-hydroxylation for CYP2C9, <i>S</i>-mephenytoin 4-hydroxylation for CYP2C19, bufuralol 1′-hydroxylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, and testosterone 6β-hydroxylation for CYP3A4. We reviewed the validation information in the literature on these reactions and other frequently used reactions, including caffeine <i>N3</i>-demethylation for CYP1A2, <i>S</i>-mephenytoin <i>N</i>-demethylation for CYP2B6, <i>S</i>-warfarin 7′-hydroxylation for CYP2C9, dextromethorphan <i>O</i>-demethylation for CYP2D6, and midazolam 1′-hydroxylation for CYP3A4. The available information indicates that we need to continue the search for better probe substrates for some enzymes. For CYP3A4-based drug interactions it may be necessary to evaluate two or more probe substrates. In many cases, the probe reaction represents a particular enzyme activity only under specific experimental conditions. Investigators must consider appropriateness of probe substrates and experimental conditions when conducting in vitro drug interaction studies and when extrapolating the results to in vivo situations.
81
Tsutomu Shimada, Hiroshi Yamazaki, Mayumi Mimura et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 2.8K citations
Medicine, Biochemistry, Pharmacology +15
Marguerite A. Butler, M. Iwasaki, F. Peter Guengerich et al. · Proceedings of the National Academy of Sciences · 1989 · 638 citations · Full text
Medicine, Pharmacology, Toxicology +17